Affordable Access

deepdyve-link
Publisher Website

Neutrophilic Asthma and Potentially Related Target Therapies.

Authors
  • Nair, Pranav1
  • Prabhavalkar, Kedar S1
  • 1 Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India. , (India)
Type
Published Article
Journal
Current drug targets
Publication Date
Jan 01, 2020
Volume
21
Issue
4
Pages
374–388
Identifiers
DOI: 10.2174/1389450120666191011162526
PMID: 31660822
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Neutrophilic asthma is generally associated with the absence of eosinophils and activation of non- predominant type 2 immunological pathways. It involves bronchial inflammation followed by different degrees of airway remodeling. Neutrophilic inflammation activates specific cellular and molecular pathways due to inhalation of environmental trigger factors such as exhaust fumes, cigarette smoke, occupation-related agents, and infections. This review discusses the involvement of neutrophils in asthma and potentially related target therapies. Corticosteroid resistance is the hallmark of neutrophilic asthma which increases disease severity and leads to difficult-to-control asthma. Patients with neutrophil-dominant asthma are characterized by low levels of (or absence of) Th2 cytokines. Due to the shortage of effective treatments for neutrophilic asthma newer biologics are being developed that target type 2 asthma symptoms and phenotypes. Understanding different biomarkers, inflammatory pathways and treatment strategies involved in neutrophilic asthma will help to decrease adverse effects related to corticosteroid insensitivity. Better insight of targets involved in neutrophilic inflammation can lead to improved therapies. Further evaluation and clinical trials of emerging biologics involved in neutrophilic asthma needs to be performed before bringing them into clinical practice. Copyright© Bentham Science Publishers; For any queries, please email at [email protected]

Report this publication

Statistics

Seen <100 times